IPHARMA has announced the initiation of two clinical trials for the treatment of patients with COVID
IPHARMA CRO has announced the initiation of two clinical trials to evaluate the efficacy of Favipiravir and Elsulfavirine on patients with COVID-19 (novel coronavirus) today.
These randomized, open-label, multicenter studies will enroll approximately 330 and 60 patients accordingly at Sites across Russia and EAEU countries.
The influenza antiviral Favipiravir, manufactured by Kromis LLC. Elsulfavirine (Viriom Inc.) is marketed in Russia and EAEU countries for the treatment of HIV infection.